Subscribe

DIGITAL EDITION

ARCHIVES

CURRENT ISSUE

Irene Malaty, MD: Identifying the Appropriate Patients for Subcutaneous Parkinson’s Disease Therapy

Dr. Irene Malaty, from the University of Florida, discusses how to identify patients who may benefit from Vyalev (foscarbidopa/foslevodopa), highlighting key indicators that a patient is ready to transition beyond

Read More
Lessons Learned from Drug Development Programs in Autism: Implications for Future Programs

Innov Clin Neurosci. 2026;23(4–6):9–16. Epub ahead of print. by Gahan Pandina, PhD; William J. Martin, PhD; Christopher Chatham, PhD; Declan Murphy, MD; Jane Myles, MSc; Robert H. Ring, PhD; and

Read More
Part 2—Jason Aldred, MD: Understanding Possible Side Effects When Treating Patients with Parkinson’s Disease
Dr. Jason Aldred, owner of Selkirk Neurology in Spokane, WA, discusses the neuropsychiatric effects and dyskinesia that patients may experience when taking Vyalev (foscarbidopa/foslevodopa).
Read More
Part 1—Jason Aldred, MD: Understanding Possible Side Effects When Treating Patients with Parkinson’s Disease
Dr. Jason Aldred, owner of Selkirk Neurology in Spokane, WA, discusses the safety profile of Vyalev (foscarbidopa/foslevodopa), notably injection site reactions and skin considerations.
Read More
January-March 2026 Digital Edition

Click the cover below to access the January-March 2026 Digital Edition

Read More
Letters to the Editor: Post-SSRI Sexual Dysfunction: Challenges and Treatment Approaches

Innov Clin Neurosci. 2026;23(1–3):5–9. Dear Editor: Selective serotonin reuptake inhibitors (SSRIs) have long been a cornerstone in the treatment of mood disorders, particularly depression and anxiety. Since their introduction in

Read More